Press release
Oncolytic Virus Cancer Therapy Market: Epidemiology, Treatments, and Key Companies | DelveInsight
Oncolytic Virus Cancer Therapy Market
Leading companies in the oncolytic virus cancer therapy space include Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, and Daiichi Sankyo. Therapies such as IMLYGIC (T-VEC), DELYTACT (G47), Olvi-Vec, RP1, and others are expected to drive growth in the oncolytic virus cancer therapy market in the coming years.
DelveInsight has released a comprehensive report titled "Oncolytic Virus Cancer Therapy - Market Insights, Epidemiology, and Forecast to 2034", providing detailed analysis of the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Oncolytic virus cancer therapy market report @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Oncolytic virus cancer therapy Market Report:
*
The United States leads the global oncolytic virus market, accounting for over 70% of its total size, significantly outpacing regions such as the EU4, UK, and Japan. Oncolytic viruses provide several advantages over other cancer immunotherapies, including potent tumor-killing effects, targeted action, and fewer side effects or resistance issues.
*
Currently, only two therapies-IMLYGIC (Amgen, approved 2015) and DELYTACT (Daiichi Sankyo, approved 2021)-have received global approval. However, the development pipeline is robust, with companies like Replimune, Genelux, Imugene, and EpicentRx driving innovation. Among these, RP1 is expected to capture roughly 40% of the market over the next decade.
*
In November 2023, the FDA granted Fast Track designation to Genelux's Olvi-Vec for the treatment of platinum-resistant or refractory ovarian cancer.
*
According to GLOBOCAN, new breast cancer cases in the U.S. are projected to rise from 274,375 in 2022 to 321,295 by 2035. DelveInsight analysis also indicates that in 2023, prostate cancer accounted for about 20% of the total eligible patient population for oncolytic virus therapies across the seven major markets (7MM).
*
Key companies developing new oncolytic virus cancer therapies include Targovax, Genelux, Imugene, EpicentRx, Replimune, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others. Promising therapies in this space include IMLYGIC (T-VEC), DELYTACT (G47), Olvi-Vec, RP1, and additional candidates.
Oncolytic virus cancer therapy Overview
Oncolytic viruses represent a distinct form of cancer therapy, functioning by selectively replicating within tumor cells, inducing immunogenic cell death, and stimulating the immune system to attack cancer. These viruses, whether naturally occurring or genetically engineered, specifically target and destroy malignant cells.
Although their mechanisms are not completely understood, oncolytic viruses primarily work through two pathways: directly destroying tumor cells (oncolysis) and indirectly enhancing the immune system's response against tumors.
They are classified into RNA and DNA viruses. RNA viruses, including reoviruses, paramyxoviruses, and picornaviruses, replicate rapidly and quickly eliminate tumor cells but have limited genetic capacity. DNA viruses, such as herpesviruses, adenoviruses, and poxviruses, replicate more slowly but can carry multiple inserted genes, enabling more complex therapeutic approaches.
Oncolytic virus cancer therapy Market Outlook
As cancer continues to be a leading cause of death worldwide, the need for innovative therapies is growing. Oncolytic viruses (OVs), which selectively infect and destroy cancer cells while stimulating the immune system, have emerged as a promising treatment approach. Market expansion is being driven by increased R&D activities, rising pharmaceutical investments, and a growing number of clinical trials.
Key milestones include the FDA and European approval of IMLYGIC (Amgen) in 2015 for unresectable melanoma, and Japan's conditional approval of DELYTACT (Daiichi Sankyo) in 2021 for malignant glioma. These approvals highlighted the potential of genetically engineered viruses to both target tumors and activate immune responses.
Although these approvals represent significant progress, ongoing clinical trials by companies such as Replimune, DNAtrix, and SillaJen are broadening the scope of OVs across multiple cancer types, underscoring their evolving role in personalized oncology.
Discover how the Oncolytic virus cancer therapy market is rising in the coming years @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Oncolytic Virus Marketed Drugs
*
IMLYGIC (T-VEC): Amgen
*
DELYTACT (G47): Daiichio Sankyo
Oncolytic virus cancer therapy Emerging Drugs
*
Olvi-Vec: Genelux
*
RP1: Replimune
Scope of the Oncolytic virus cancer therapy Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Oncolytic virus cancer therapy Companies: Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others
*
Key Oncolytic virus cancer therapy Therapies: IMLYGIC (T-VEC), DELYTACT (G47), Olvi-Vec, RP1, and others
*
Oncolytic virus cancer therapy Therapeutic Assessment: Oncolytic virus cancer therapy current marketed and Oncolytic virus cancer therapy emerging therapies
*
Oncolytic virus cancer therapy Market Dynamics: Oncolytic virus cancer therapy market drivers and Oncolytic virus cancer therapy market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Oncolytic virus cancer therapy Unmet Needs, KOL's views, Analyst's views, Oncolytic virus cancer therapy Market Access and Reimbursement
To know what's more in our Oncolytic virus cancer therapy report, visit https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Oncolytic virus cancer therapy Market Report:
*
Oncolytic virus cancer therapy market report covers a descriptive overview and comprehensive insight of the Oncolytic virus cancer therapy Epidemiology and Oncolytic virus cancer therapy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Oncolytic virus cancer therapy market report provides insights into the current and emerging therapies.
*
The Oncolytic virus cancer therapy market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Oncolytic virus cancer therapy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oncolytic virus cancer therapy market.
Got queries? Click here to know more about the Oncolytic virus cancer therapy market Landscape [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Oncolytic virus cancer therapy Patient Share (%) Overview at a Glance
5. Oncolytic virus cancer therapy Market Overview at a Glance
6. Oncolytic virus cancer therapy Disease Background and Overview
7. Oncolytic virus cancer therapy Epidemiology and Patient Population
8. Country-Specific Patient Population of Oncolytic virus cancer therapy
9. Oncolytic virus cancer therapy Current Treatment and Medical Practices
10. Unmet Needs
11. Oncolytic virus cancer therapy Emerging Therapies
12. Oncolytic virus cancer therapy Market Outlook
13. Country-Wise Oncolytic virus cancer therapy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Oncolytic virus cancer therapy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Oncolytic virus cancer therapy Market Outlook 2034 [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Oncolytic virus cancer therapy Pipeline Insights, DelveInsight
"Oncolytic virus cancer therapy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oncolytic virus cancer therapy market. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided, which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-cancer-therapy-market-epidemiology-treatments-and-key-companies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Cancer Therapy Market: Epidemiology, Treatments, and Key Companies | DelveInsight here
News-ID: 4185409 • Views: …
More Releases from ABNewswire
Achondroplasia Market Overview: Epidemiology, Treatment Landscape, Key Players | …
DelveInsight's Achondroplasia Market Insights, Epidemiology, and Market Forecast 2034 report provides a detailed outlook of the current and future Achondroplasia treatment market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future Achondroplasia market share of all therapies.
Achondroplasia treatments, including VOXZOGO (vosoritide), RBM-007, SAR-442501, low-dose infigratinib, and others, are anticipated…
Laparoscopic Devices Market Poised for Steady Growth Through 2032, Driven by Inn …
Laparoscopy Devices by Product Type, Application, End-User, and Geography is expected to grow at a steady CAGR forecast till 2030 owing to the increase in incidence of cancer such as gastrointestinal and colorectal cancer, growing adoption of minimally invasive surgeries across the globe, and growing advancement in Laparoscopy technology.
The global laparoscopic devices market was valued at USD 11.35 billion in 2023 and is expected to grow at a CAGR of…
Catheter-Related Bloodstream Infections Market: Epidemiology, Treatments, and Ke …
The Catheter Related Bloodstream Infection Drugs Market Report also covers current catheter-related bloodstream infection treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Key companies in this space include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, and Fresenius Medical Care. Therapies for catheter-related bloodstream infections, such as DEFENCATH and MINO-LOK, are anticipated to drive market growth over the coming years.
DelveInsight has released…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
